




AGalunisertib: C₂₂H₁₉N₅O**B****C**

Figure S1. Transferred TGFBR1-Deficient CTLs produce GranzymeB in the pancreas tumor microenvironment

(A) Chemical structure of the TGFBR1 inhibitor Galunisertib (LY2157299). **(B)** P48-Cre x LSL-KRAS^{G12D} (KC) mice were generated to target conditional expression of oncogenic KRAS^{G12D} to the exocrine pancreas. Mice were allowed to develop neoplastic disease, and subsequently administered either 2x10⁶ wild type (WT CD8⁺) or TGFBR1-deficient (Tgfr1^{+/-} CD8⁺) CD8⁺ T-cells retroorbital injection. Similarly, KC mice crossed to *Tgfr1* haplo-insufficient animals (KC/Tgfr1^{+/-}). Tissues were collected and dual stained with CD3 and GranzymeB. **(C)** CD3/GranzymeB dual positive cells were quantified by two investigators and averages displayed ± S.E.M. (*p < 0.05, N=3-6/group).